IP Verse

Posaconazole Intravenous Solution Formulations Stabilized By Substituted Beta-Cyclodextrin

Patent No. EP3391890 (titled "Posaconazole Intravenous Solution Formulations Stabilized By Substituted Beta-Cyclodextrin") was filed by Merck Sharp & Dohme on Jun 24, 2011. The application was issued on Aug 25, 2021.

Patent Summary

Stable intravenous formulation of posaconazole, an antifungal drug, for treating fungal infections. The formulation uses a modified cyclodextrin called Captisol and the chelating agent EDTA to solubilize and stabilize posaconazole in water. The cyclodextrin forms a complex with posaconazole to increase solubility, while EDTA helps maintain stability. The formulation can be diluted for infusion without precipitation, providing a practical and stable intravenous option for posaconazole administration.

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ETHYPHARMMay 25, 2022LLR
FRESENIUS KABI DEUTSCHLANDMay 25, 2022FRESENIUS KABI DEUTSCHLAND
GENERICS UKMay 25, 2022ELKINGTON AND FIFE
AERAMay 25, 2022AERA

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3391890

MERCK SHARP & DOHME
Application Number
EP18171672A
Filing Date
Jun 24, 2011
Status
Granted And Under Opposition
Jul 23, 2021
Publication Date
Aug 25, 2021
External Links
Slate, Register , Google Patents